Impact of an HCV Test and Treat Campaign on Hepatitis C Incidence in the ANRS PREVENIR PrEP study

Geoffroy Liegeon^{1,2}, Constance Delaugerre^{2,3,4}, Lydie Beniguel⁵, Salima Barkat⁵, Jade Ghosn^{2,6,7}, Sarah Maylin³, Romain Palich⁸, Gilles Pialoux⁹, Laurence Slama¹⁰, Mohamed Ben Mechlia¹¹, Dominique Costagliola⁵, Lambert Assoumou⁵, Jean-Michel Molina^{1,2,4}, for the ANRS PREVENIR Study group


¹Service des maladies infectieuses, Assistance publique - Hôpitaux de Paris, France ⁴INSERM UMR1342, Paris, France ⁵Sorbonne ⁵Sorbonne ⁴INSERM UMR1342, Paris, France ⁵Sorbonne ⁵S Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France ⁷ Université Paris Cité, INSERM, UMRS 1137 IAME, Paris, France ⁸Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁷ Université Paris Cité, INSERM, UMRS 1137 IAME, Paris, France ⁸Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université Paris Cité, INSERM, UMRS 1137 IAME, Paris, France ⁸Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université Paris Cité, INSERM, UMRS 1137 IAME, Paris, France ⁸Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université Paris, France ⁹ Université, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université Paris Cité, INSERM, UMRS 1137 IAME, Paris, France ⁸ Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service des Maladies, Hôpital Bichat-Claude Bernard, Paris, France ⁹ Université, Service Bernard, Paris, France ⁹ Université, S des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies Infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuses, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des maladies infectieuse, AP-HP, Hôpital Tenon, Paris, France ¹⁰ Service des m

BACKGROUND

Men who have sex with men (MSM) on HIV pre-exposure prophylaxis (PrEP) have an increased risk of hepatitis C virus (HCV) infection. Early detection of HCV infection through HCV nucleic acid testing (NAT) and core antigen (cAg) may significantly reduce the time to treatment initiation among PrEP users, potentially preventing further HCV infections at the community level. We evaluated the impact of a direct HCV test and treat campaign on hepatitis C incidence in the ANRS PREVENIR PrEP study.

METHODS

The ANRS PREVENIR study, launched on May 2017, is an ongoing prospective cohort study of oral PrEP implementation at 26 sites in the Paris region in France. From January 1st, 2020, to June 30th, 2021, all participants were invited for HCV testing using HCV NAT and core antigen, with positive cases immediately treated with direct-acting antivirals (DAAs).



Study objectives:

- To evaluate the incidence of acute HCV infection before and after implementation of the "Test and Treat" strategy.
- evaluate the time to treatment - To implementation of the "Test and Treat" strategy and treatment outcomes.
- To understand the socio-demographics and behavioral factors associated with acute HCV infection.

Analysis:

- We included in the analysis all MSM enrolled in the ANRS PREVENIR study before the initiation of the testing campaign (01st January 2020).
- Descriptive statistics were used to describe the study population at baseline. - We used the Kaplan-Meier method to analyze time to treatment initiation and
- compared it across the three study periods using a Cox model.
- We used a Poisson model to assess factors associated with incident HCV infections, including campaign period, Monkeypox period, COVID-19 lockdown, number of sexual partners in the past 6 months, number of condomless anal sex in the past month, perception of sexual risk-taking, intravenous drug use, chemsex practice, and meeting casual partners at sex parties. Only variables with univariable p-value < 0.20 were included in the multivariable model.



NOTES

Contact information. Dr. Geoffroy Liegeon, AP-HP | Saint-Louis Hospital, Paris, France. Contact: geoffroy.liegeon@aphp.fr Financial support. The ANRS PREVENIR study was supported by the ANRS/MIE; SIDACTION; Gilead Sciences, and the Région Ile-de-France. This sub-study was supported by a grant from Gilead Sciences. Acknowledgments. We are grateful to the study participants; to ANRS - Maladies Infectieuses Emergentes (MIE); to SIDACTION and the Ile de France region for their grant support; and to Gilead Sciences for its grant.

Post-Campaign Period 2 Years et 10 Months

ALT every 6 months Annual HCV serology

May 2024

initiation before and after the

We observed a significant reduction in HCV incidence among MSM using PrEP following an HCV test and treat campaign. Additional factors, such as concurrent epidemics (COVID-19, monkeypox), shifts in sexual and drug use behaviors, and new recommendations for early treatment of acute HCV infection, may also have contributed to this trend.

RESULTS

Characteristics of participants at baseline (N=3215):

-	للرە

Median age: 36 years (IQR 29-43) 85.9% with a university degree

41.7% are PrEP-naive.



45% have a regular sexual partner. Median of 10 partners in the last 3 months (IQR: 5-20). Median of 2 condomless sexual intercourse in the past month 34.8% used a condom during the most recent sexual intercourse



14.3% practiced chemsex 1.9% used intravenous drug 22.4% participated in sex parties


Testing campaign and incident HCV infections:

	paign Perio and 8 Mont	- 1	Cam « Test ar 1 Year and	
	ery 6 months ICV serolog		HCV NAT + HCV s	
May 2017 N=3	3050	Janu	i <mark>ary 2020</mark> N=2	<u>23</u>
	157	•	%) participa the two ca paign 1 (3	ar
	nfections) treated	Cam	paign 2 (9 N Both campa	Λ
		HC\ nti-HC	V RNA: N= / antigen: N V antibodie infections	= ≥s
	IJ			


84.8% born in France 85.8% employed




8 (0,2%) with a HCV infection at baseline



Incidence of HCV infection during the study:





Factors associated with HCV incident cases:

Multivariate Model

Post-campaign vs. p During campaign vs. During the Monkey Perception of Sexua **Chemsex during last** Use of intravenous Meeting casual sexu

59 cases of HCV infection in 56 participants

0752

Treated and cured infections: 48/59 (81%)

- Treated infection with indeterminate status: 2/59 (3%)
- Untreated and cured infections: 8/59 (14%)
- Untreated infection with indeterminate status 1/59 (2%)

l (Poisson model)	Incidence Rate Ratio (95%CI)	P-value
pre-campaign	0.47 (0.22, 0.98)	0.043
s. pre-campaign	0.69 (0.37, 1.27)	0.240
ypox Period vs. Outside	0.62 (0.13, 2.86)	0.516
al Risk-Taking vs. No Perception	1.37 (0.80, 2.35)	0.242
t intercourse vs. None	1.69 (0.95, 2.98)	0.080
drugs vs. No use	4.51 (1.96, 10.37)	0.003
ual partners at sex parties vs. Not	2.14 (1.25, 3.66)	0.006